News >

EU Panel Backs Lenalidomide- and Pomalidomide-Based Triplets for Myeloma

Gina Columbus @ginacolumbusonc
Published: Friday, Mar 29, 2019

Nadim Ahmed

Nadim Ahmed

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has granted positive opinions to 2 triplet regimens with immunomodulatory agents (IMiDs) for patients with multiple myeloma.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication